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MicroRNA-26a Is Strongly Downregulated in
Melanoma and Induces Cell Death through
Repression of Silencer of Death Domains (SODD)
Steven N. Reuland1, Shilo M. Smith1, Lynne T. Bemis2, Nathaniel B. Goldstein1, Adam R. Almeida1,
Katie A. Partyka1, Victor E. Marquez3, Qinghong Zhang1, David A. Norris1,4,5 and Yiqun G. Shellman1,5
Melanoma is an aggressive cancer that metastasizes rapidly and is refractory to conventional chemotherapies.
Identifying microRNAs (miRNAs) that are responsible for this pathogenesis is therefore a promising means of
developing new therapies. We identified miR-26a through microarray and quantitative reverse-transcription–PCR
(qRT-PCR) experiments as an miRNA that is strongly downregulated in melanoma cell lines as compared with
primary melanocytes. Treatment of cell lines with miR-26a mimic caused significant and rapid cell death
compared with a negative control in most melanoma cell lines tested. In surveying targets of miR-26a, we found
that protein levels of SMAD1 (mothers against decapentaplegic homolog 1) and BAG-4/SODD were strongly
decreased in sensitive cells treated with miR-26a mimic as compared with the control. The luciferase reporter
assays further demonstrated that miR-26a can repress gene expression through the binding site in the 30
untranslated region (30UTR) of SODD (silencer of death domains). Knockdown of these proteins with small
interfering RNA (siRNA) showed that SODD has an important role in protecting melanoma cells from apoptosis
in most cell lines sensitive to miR-26a, whereas SMAD1 may have a minor role. Furthermore, transfecting cells
with a miR-26a inhibitor increased SODD expression. Our findings indicate that miR-26a replacement is a
potential therapeutic strategy for metastatic melanoma, and that SODD, in particular, is a potentially useful
therapeutic target.
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INTRODUCTION
Metastatic melanoma is a devastating disease that is notor-
iously resistant to traditional chemotherapies. Recent advances
in the use of BRAF inhibitors have marked the first serious
progress in treating malignant melanoma in nearly 30 years
(Buzaid, 2004; Cummins et al., 2006; Gogas et al., 2007). Yet,
in spite of the success of these new drugs, they are only
appropriate in roughly one-half of patients with melanomas
harboring BRAF V600E mutations, and relapse and resistance
are inevitable (Flaherty, 2010; Ades and Metzger-Filho, 2012).
Thus, there is still a pressing need for therapies using new
approaches.
Dysregulation of important cell proliferation pathways
and tumor suppressors is a necessary step in oncogenesis.
Recently, microRNAs (miRNA), short RNAs that target
expressed mRNA for degradation, have gained much attention
for the role they have in affecting protein expression in cancer
tissues (Esteller, 2011; Kasinski and Slack, 2011; Sandhu and
Garzon, 2011). Release 18 of miRBase (www.mirbase.org) has
nearly 1,900 unique mature miRNAs annotated for the human
genome (Kozomara and Griffiths-Jones, 2011), and 60% of all
genes may be regulated by miRNAs (Friedman et al., 2009).
Thus, miRNAs represent an important regulatory layer that
can affect gene expression above and beyond other cellular
mechanisms. The small size and natural occurrence of
miRNAs have made them attractive for use in therapy. New
therapies are currently being developed based primarily on
miRNA replacement, as miRNAs are most commonly
downregulated in cancers and are thought to act as tumor
suppressors (Kumar et al., 2007). In addition, miRNA studies
can be useful in identifying potential therapeutic targets that
may act upstream or downstream of miRNAs.
In this study, we identified miR-26a in a microarray screen
and subsequent quantitative reverse-transcription–PCR (qRT-
PCR) validation as being strongly downregulated in melanoma
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cells compared with primary melanocytes. In surveying
possible targets of miR-26a, we found two proteins, SMAD1
(mothers against decapentaplegic homolog 1) and BAG family
molecular chaperone regulator 4 (BAG4, also known as
silencer of death domains (SODD), hereafter referred to only
as SODD), that were strongly downregulated upon miR-26a
treatment. SODD and to a lesser extent SMAD1 appear to be
necessary to prevent apoptosis in multiple melanoma lines.
We discuss the potential for melanoma therapy through
miR-26a replacement or direct targeting of these proteins.
RESULTS
Microarray analysis and qRT-PCR identified miR-26a as strongly
downregulated in melanomas compared with melanocytes
We performed microarray analysis to identify miRNAs that are
significantly changed in human melanoma cell lines com-
pared with melanocytes. We found a number of miRNAs that
were either downregulated or upregulated (Table 1). We then
performed qRT-PCR of samples from numerous melanoma
cell lines and two different primary melanocyte cultures at
different passages under different culture conditions (Figure 1
and data not shown). Results indicated that miR-26a was
strongly downregulated in all of the melanoma cell lines
tested compared with the melanocytes. Although levels of
miR-26a varied considerably among both melanomas and
melanocytes, the levels were strikingly lower in melanomas,
from 4-fold to as much as 50-fold (average of 17.7-fold) lower
than in melanocytes (Figure 1). These results clearly demon-
strate that miR-26a is strongly downregulated in melanoma
cells, validating our microarray results. As miR-26a showed
the strongest and most consistent difference among the
miRNAs that we tested (Figure 1 and data not shown), in this
study, we focused on miR-26a.
Transfection with miR-26a mimic decreases viability and
increases apoptosis in multiple melanoma cell lines
To test whether low levels of miR-26a facilitate melanoma cell
viability, we transfected multiple melanoma cell lines with miR-
26a mimic. Viability assays, as shown in Figure 2a, demonstrate
massive reduction in viability starting at 72 hours and accel-
erating by 96 hours after transfection with miR-26a mimic
compared with transfection with negative control small inter-
fering RNA (siRNA) in most cell lines tested, but not in normal
primary melanocytes HEMNLP2. Statistical analyses indicated
that, at 72 hours, the viabilities of miR-26a-transfected cells
from RPMI7951, WM278, WM852c, and 1205Lu were sig-
nificantly different from those of control-transfected cells
(Po0.05). At later time points, in addition to the same mela-
noma cell lines above, the viability of miR-26a-transfected
HT-144 was also significantly different from the controls. On
the other hand, melanoma cell lines A375 and SK-MEL-28 and
primary melanocytes HEMNLP2 were resistant to miR-26a.
Annexin V assays shown in Figure 2b corroborate the
viability assays and demonstrate that apoptosis is a major
mechanism of reduced viability in some cell lines. Statistical
analyses indicated that miR-26a significantly increased the
percentage of total Annexin Vþ cells in HT-144, WM852c,
WM278, and 1205Lu (Figure 2b). The appearance of the cells
Table 1. MicroRNAs (miRNAs) identified as down- or
upregulated in melanomas compared with normal
melanocytes by rank product statistical analysis
Fold expression
(melanoma/melanocyte)
Downregulated in melanoma
hsa|let-7e 0.5
hsa|miR-1234 0.2
hsa|miR-125a-5p 0.3
hsa|miR-130a 0.5
hsa|miR-20b 0.7
hsa|miR-26a 0.6
hsa|miR-30a 0.6
hsa|miR-361-5p 0.6
hsa|miR-363 0.1
hsa|miR-494 0.4
hsa|miR-508-3p 0.5
hsa|miR-509-3-5p 0.3
hsa|miR-513a-5p 0.2
hsa|miR-923 0.5
Upregulated in melanoma
hsa|miR-100 2.0
hsa|miR-222 2.7
hsa|miR-23b 2.1
hsa|miR-27b 2.4
hsa|miR-31 2.5
hsa|miR-99a 2.4
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Figure 1. Scatter plot of quantitative reverse-transcription–PCR (qRT-PCR)
results for miR-26a expression showing melanocytes versus melanoma cell
lines. Melanocytes include two different primary melanocyte lines (HEMNLP
and HEMNLP2) at different passages and with different culture conditions (with
or without fetal bovine serum (FBS)). Melanomas include 10 different
established cell lines under standard culture conditions (see Materials and
Methods for a list of cell lines). All results were normalized to RNU1A as an
internal standard, and denote relative expression compared with one of the
melanocyte lines set at 1.0. Melanoma lines had an average of 17.7-fold less
miR-26a compared with melanocytes, Po0.0001.
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(Figure 2c) is consistent with the viability and Annexin V
assays, showing reduced proliferation and cell death. Cell
lines, A375 and SK-MEL-28, were resistant to the effects of the
miR-26a mimic, as were primary melanocytes, HEMNLP2
(Figure 2c). Furthermore, immunoblots of lysates from cells
transfected with miR-26a mimic showed that miR-26a
also increased poly (ADP-ribose) polymerase cleavage in
miR-26a-sensitive cells compared with those transfected with
negative control siRNA (Figure 3a), further demonstrating that
miR-26a induces apoptosis in these cells.
To test whether variations in transfection efficiency could
account for the differences in sensitivity to miR-26a mimic,
we used an identical protocol to transfect multiple melanoma
cell lines and melanocytes with Allstars Negative Control
siRNA conjugated with a fluorophore. Fluorescence micro-
scopy indicated transfection efficiencies near 100%, even in
cells resistant to miR-26a mimic (Supplementary Figure S1
online). In addition, we measured miR-26a in both sensitive
and resistant cell lines transfected with miR-26a mimic and
negative control by qRT-PCR. miR-26a levels were on the
order of 103-fold higher in cells transfected with miR-26a
compared with those transfected with negative control at
72 hours after transfection (928- and 3,866-fold higher in HT-
144 and SK-MEL-28 cells, respectively). We thus concluded
that differences in transfection efficiency or miRNA stability
were not responsible for differences in sensitivity to miR-26a.
SMAD1 and SODD protein levels are decreased in miR-26a
mimic-treated cells, inhibition of miR-26a increases SODD
levels, and luciferase reporter assays confirm that SODD is a
target of miR-26a
Melanoma cells treated with miR-26a mimic and negative
control siRNA were collected after 72 hours and lysed for
immunoblotting. We tested these lysates for a variety of
possible targets to miR-26a, including EZH2, cyclins D2 and
E2, metadherin, glycogen synthase kinase-3b, SMAD1, and
SODD. Each of these proteins, with the exception of SODD,
has been previously identified as a target of miR-26a
(Luzi et al., 2008; Sander et al., 2008; Kota et al., 2009;
Mohamed et al., 2010; Zhang et al., 2011). SODD was
identified in the TargetScan database as having a potential
30UTR binding site for miR-26a close to the stop codon, with
99 percentile context score, in addition to two other binding
sites, rendering it a strong candidate target. We found sharp
reductions in the levels of SMAD1 and SODD in most
sensitive cell lines, but not in the other putative
targets (Figure 3a and data not shown). Resistant cell lines,
A375 and SK-MEL-28, showed little or no reductions in these
proteins. All sensitive cell lines showed reduction in at least
one of these two proteins ofX50%, although 1205Lu showed
no noticeable reduction in SODD after miR-26a treatment.
To further test the role of miR-26a in targeting SODD, a
putative and previously unreported target, we transfected
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Figure 2. Treatment with miR-26a mimic induces cell death in several melanoma cell lines. (a) Time-course MTS assays for cells transfected with 50 nM miR-26a
mimic. Results for each cell line at each time point represent the viability of cells transfected with miR-26a mimic as a percentage of those transfected with
negative control. Error bars represent SEM of at least three replicates. See Results section for statistical significance. (b) The Annexin V assays of cells transfected
with 50 nM miR-26a or negative control for 96 hours. *P-values o0.05 for comparisons between miR-26a mimic and negative control cells. Error bars represent
SEM of at least two independent experiments. (c) Visual appearance of cells after 96 hours of treatment. Scale bar in top left image¼ 0.5 mm.
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primary melanocytes, HEMNLP2, and two melanoma cell
lines that are sensitive to miR-26a, HT-144, and WM852c,
with an miRNA inhibitor specific to miR-26a. Lysates of these
cells were compared with those transfected with a negative
control inhibitor by immunoblot. We found noticeably
increased levels of SODD in cells treated with the miR-26a
inhibitor at 72 hours (Figure 3b), indicating that endogenous
miR-26a has a repressive effect on SODD.
To further confirm the role of miR-26a in regulating SODD,
we constructed a dual luciferase reporter system with 479 base
pairs (bp) of the 568 bp SODD 30UTR from the complemen-
tary DNA of a melanoma cell line containing the miR-26a
binding site downstream of the Renilla luciferase gene
(Figure 3c). We then cotransfected HEK293 cells with both
miRNA mimics (miR-26a or negative control) and reporter
constructs (two different clones of the reporter plasmids
containing SODD 30UTR or empty vector without any 30UTR).
The dual luciferase assays showed that at 48 hours after
transfection, miR-26a significantly decreased relative lucifer-
ase activity compared with the negative control for both
clones with the construct containing the SODD 30UTR (0.74
and 0.68, P¼ 0.002 and 0.0013, respectively; Figure 3c). In
contrast, there was no significant difference in relative lucifer-
ase activity for the empty vector between miR-26a and control
cotransfections (1.02, P¼0.82). In addition, we also con-
structed reporter plasmids containing a shorter SODD 30UTR
with the same miR-26a binding site, wild-type or mutated
(Supplementary Figure S2 online). The luciferase assays showed
that 48 hours after transfection, miR-26a significantly decrea-
sed the relative Renilla luciferase activity when cotransfected
with the construct containing the wild-type binding site instead
of the mutant binding site (0.52, Po0.0001; Supplementary
Figure S2 online). In contrast, mutations in the miR-26a binding
site of the 30UTR in the reporter plasmid markedly decreased
relative miR-26a repression of luciferase activity (0.88 vs. 0.52,
P¼ 0.0014; Supplementary Figure S2 online). These results
demonstrated that miR-26a can repress gene expression
through the miR-26a binding site in the SODD 30UTR.
Knockdown of SODD, and to a lesser extent of SMAD1, induces
cell death in melanoma cell lines sensitive to miR-26a
To test whether miR-26a targeting of SMAD1 and/or SODD
was responsible for the cell death observed upon treatment
with miR-26a mimic, we knocked down these transcripts in
multiple melanoma cell lines using siRNA. Cell lines were
treated with up to 25 nM of total siRNAs against SMAD1
(siSMAD1) or SODD (siSODD), or both together for 120 hours
and subjected to MTS assays. Cell lines WM278, HT-144, and
WM852c all showed significant reduction in viability after
treatment with siSODD and for the combination, and HT-144
and WM278 showed a slight reduction in viability with
siSMAD1 treatment compared with negative control siRNA
(Figure 4a; for concentration-dependent results, see
Supplementary Figure S3 online). Cell lines 1205Lu and SK-
MEL-28 showed no reduction in viability, whereas A375
showed only a slight reduction in viability with siSODD
treatment compared with the control (Figure 4a). Similar
results were found for the other two siRNAs (not shown).
Annexin V assays after 120 hours of siRNA treatments for cell
lines HT-144, WM852c, and WM278 demonstrated a sig-
nificant apoptotic population ranging from 17 to 26% upon
siSODD treatment, and minor apoptosis (B2–8%) for siS-
MAD1 treatment (Figure 4b) above the control. 1205Lu
showed only slight apoptosis (B5%) with siSODD treatment.
Cell lines SK-MEL-28 and A375 were essentially unaffected by
siRNA treatments, according to the Annexin V assays. The
appearance of the cells (Figure 4c) also indicated cell death for
lines sensitive to siSODD and was similar to that with miR-
26a treatment. Western blotting showed strong knockdown of
the respective proteins in all cell lines treated with siSMAD1
and siSODD, except for SK-MEL-28, which had only slight
knockdown (Figure 4d). Results from both MTS and Annexin V
assays upon siSODD treatment are broadly consistent
with results for miR-26a treatments, although there is the
major exception of cell line 1205Lu. Treatment with siSMAD
was similarly consistent with miR-26a results, though its
effects were very small.
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Figure 3. SODD (silencer of death domains) is a target of miR-26a. (a) Immunoblot. Cells were transfected with miR-26a mimic (26a) or negative control
(c.) for 72 hours. Quantifications are the ratios of the proteins to tubulin with controls set to 1.0. SMAD1, mothers against decapentaplegic homolog 1. (b)
Immunoblot. Cells were transfected with 50 nM miR-26a inhibitor (26aI) or miScript inhibitor negative control (c.). (c) Dual-luciferase reporter assay. Luciferase
reporter vectors containing SODD 30 untranslated region (30UTR; clones 1 and 2) or empty vectors were used. Relative luciferase activity was significantly
decreased with miR-26a cotransfection (0.74 and 0.68, P¼ 0.002 and 0.0013, respectively) compared with control mimic for the constructs containing the
SODD 30UTR, but not for the empty vector (1.02, P¼ 0.82). Error bars represent SD of three replicates. *P-valueo0.05. PARP, poly (ADP-ribose) polymerase.
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DISCUSSION
We identified miR-26a in a microarray screen and subsequent
qRT-PCR validation as being strongly downregulated in
melanoma cells compared with primary melanocytes. Prior
studies of miRNAs in melanoma have identified a number of
miRNAs that are involved in melanoma progression (Howell
et al., 2010; Mueller and Bosserhoff, 2010; Bell and Levy,
2011; Bonazzi et al., 2012). These include two miRNAs
that our analysis identified as upregulated, miR-27b and
miR-222. However, to the best of our knowledge, none of
the miRNAs that we identified as downregulated have been
previously implicated in melanoma, although several
miRNAs, in addition to miR-26a, such as miR-let7e, miR-
494, and miR-30a, are known to be downregulated in other
cancers (Mitra et al., 2011; Olaru et al., 2011; Kumarswamy
et al., 2012).
Downregulation or polymorphisms of miR-26a have pre-
viously been implicated in a variety of cancers, including
nasopharyngeal carcinoma (Lu et al., 2011), breast cancer
(Zhang et al., 2011), hepatocellular carcinoma (Kota et al.,
2009), oral cancer (Clague et al., 2010), and colon cancer
(Boni et al., 2011). Kota et al. (2009) have successfully
demonstrated miR-26a replacement therapy in a mouse
model of hepatocellular carcinoma. In addition, downregu-
lation of miR-26a appears to have roles in other diseases
(Leeper et al., 2011).
We found that treatment of melanoma cell lines with a miR-
26a mimic induced substantial cell death in multiple mela-
noma lines, but not in primary melanocytes, indicating that
reduction of miR-26a is necessary for the survival of most
melanomas. However, we found melanoma cell lines resistant
to the mimic, including A375 and SK-MEL-28, showing that in
at least some melanomas, compensatory mechanisms must
exist and/or there is incomplete degradation of miR-26a
targets. Experiments with fluorescently labeled siRNA demon-
strated that transfection efficiency with our protocol was
extremely high, and qRT-PCR experiments showed high
miR-26a levels in cells transfected with miR-26a mimic,
including resistant cells. Therefore, it is highly unlikely that
resistance was the result of insufficient miR-26a expression.
Among the sensitive cell lines was RPMI7951, which is a p53-
null line (Reuland et al., 2011), indicating that the mechanism
of cell death is not p53 dependent.
We searched for putative targets of miR-26a by first testing
targets previously reported in other studies. EZH2, for exam-
ple, is commonly cited as an important target of miR-26a
(Sander et al., 2008; Wong and Tellam, 2008; Alajez et al.,
2010; Zhang et al., 2011). Although we found some reduction
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Figure 4. The effects of knocking down SODD (silencer of death domains). (a) MTS assays after 120 hours of treatment with 25 nM total small interferring RNA
(siRNA) against SMAD1 (siSMAD1-a or siSMAD1-b), or SODD (siSODD-a or siSODD-b) normalized to the control siRNA. Shown are results using siSMAD1-a and
siSODD-a; similar results were found for the other two siRNAs (not shown). Error bars represent SEM of three replicates. SMAD1, mothers against decapentaplegic
homolog 1. (b) The Annexin V assay results after 120 hours of treatment with 25 nM siRNA normalized to the control. The y axis represents the increase in the
percentage of total Annexin V–positive cells compared with negative control–transfected cells. Error bars represent SEM of at least two independent experiments.
(c) Visual appearance of cells from (a). Scale bar¼ 0.5 mm. (d) Immunoblots of siRNA-treated-cells from (b). Lane 1, control; lanes 2/4, siSMAD1 (siSMAD1-a and
siSMAD1-b); lanes 3/5, siSODD (siSODD-a and siSODD-b).
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of EZH2 in some miR-26a-treated cells, the reduction was low
and inconsistent (Figure 3a). In addition, we treated cell lines
with the histone methylation inhibitor DZNep, which depletes
EZH2 (Tan et al., 2007), and found that it had little effect even
at high doses (Supplementary Figure S4 online), with the
paradoxical exception of cell line A375 that, although sensi-
tive to DZNep, is resistant to miR-26a treatment. We therefore
concluded that miR-26a was not killing melanoma cells
through EZH2 knockdown.
Other previously validated targets of miR-26a include
glycogen synthase kinase-b (Mohamed et al., 2010), cyclins
D2 and E2 (Kota et al., 2009; Lu et al., 2011; Zhu et al., 2012),
metadherin (Zhang et al., 2011), and SMAD1 (Luzi et al.,
2008; Nigam et al., 2010). Of these, only SMAD1, a
transcription factor involved in bone morphogenic protein
signaling, showed clear and consistent repression by miR-26a
in the melanoma cell lines we tested (Figure 3a and data not
shown). We also queried the TargetScan database to identify
other potential targets of miR-26a. A binding site in the 30UTR
of SODD was predicted with a 99 percentile context score,
and is also close to the stop codon (position 130–137). In
addition, SODD encodes a member of the BAG1 family, a
potential antiapoptotic protein (Antoku et al., 2001). As with
SMAD1, we found that miR-26a caused strong and consistent
downregulation of SODD protein. We also found that the
inhibition of endogenous miR-26a in normal melanocytes and
two melanoma cell lines leads to increased SODD levels
(Figure 3b), and we further found that miR-26a can repress
the gene expression through the native SODD 30UTR using
luciferase reporter assays (Figure 3c and Supplementary Figure
S3 online). Taken together, the evidence indicates that SODD
is a target of miR-26a in melanoma cells.
To test the possible involvement of SMAD1 and/or SODD in
melanoma cell death induced by miR-26a replacement, we
specifically knocked down these two proteins with siRNA. The
results indicated that SODD expression, at least, is necessary
for preventing cell death in multiple melanoma lines. We
found only minor effects by knocking down SMAD1 alone,
although the possibility remains that this protein has crucial
roles under different contexts. Interestingly, one cell line that
was highly sensitive to miR-26a mimic, 1205Lu, was com-
pletely insensitive to siSODD and siSMAD1 treatments (com-
pare Figures 2 and 4). This was likely not because of
insufficient knockdown (Figure 4d), but rather implies that
there are additional targets of miR-26a that account for the
sensitivity of 1205Lu to the mimic. It is well known that
miRNAs have many targets and that these vary according to
the cell type in a context-dependent manner (Didiano and
Hobert, 2006). It is not clear to us why this cell line is highly
sensitive to the miRNA mimic yet not affected by the
knockdown of SODD or SMAD1. We hypothesize that one
or more targets, other than SODD or SMAD1, mediate the
effects of miR-26a in the 1205Lu cell line. The identification of
these additional targets and the potentially complex
mechanism of their interplay will require further study.
Similarly, the resistance of two melanoma cell lines to both
miR-26a and the siRNAs against SMAD1 and SODD would
seem to indicate that these proteins are essential only in a subset
of melanoma cells. Significant knockdown of both proteins
was achieved in siRNA-treated A375 cells (Figure 4d), and yet
this had no effect on viability. Taken together, it appears that
although SODD is a potentially critical target of miR-26a in
many melanomas, its knockdown by miR-26a treatment can
only cause cell death in a subset of melanoma cell lines.
To the best of our knowledge, SODD has not been
previously reported as a target of miR-26a and as an
antiapoptotic protein in melanoma. SODD is known as an
inhibitor of the death domains of the tumor necrosis factor
(TNF) receptor 1, preventing trimerization of the receptor
subunits in the absence of specific signaling (Jiang et al., 1999;
Miki and Eddy, 2002). Upon TNF-a binding, the subunits of
the receptor trimerize and SODD is quickly released.
Activated TNF receptors can then lead to either apoptosis or
NF-kB activation. In addition, SODD is known to interact with
Hsp70, death receptor 3, and the antiapoptotic protein Bcl-2
(Jiang et al., 1999; Antoku et al., 2001; Brockmann et al.,
2004). SODD is overexpressed in pancreatic cancer and leads
to resistance of TNF-a-induced cell death (Ozawa et al.,
2000), and increased SODD is correlated with the severity
of acute lymphoblastic leukemia in children, and the
downregulation of SODD and NF-kB induces apoptosis (Tao
et al., 2007). As the balance between pro- and anti-apoptotic
signaling in TNF receptor 1 activation is critical in melanoma
(Ivanov et al., 2003), it is likely that SODD acts to tip the
balance away from cell death and toward NF-kB activation,
which is constitutively active in melanoma and important in
its progression (Poser and Bosserhoff, 2004; Madonna et al.,
2012). In addition, SODD could have a role in the
antiapoptotic functions of Bcl-2 family members, as we and
others have found that these proteins are critical mediators of
cell survival in melanoma (Reuland et al., 2011, 2012).
Further study is needed to test these and other hypotheses,
but regardless, our data indicate that SODD is essential for cell
survival of a subgroup of melanoma cells without any other
triggers, suggesting that SODD is a potential target for
treatment of certain types of melanoma.
In conclusion, we have found that miR-26a is strongly
downregulated in melanoma cells compared with normal
melanocytes, and that replacement of miR-26a induces cell
death in multiple cell lines. We have identified the antiapop-
totic protein SODD as a target of miR-26a, and found that
specific knockdown of SODD produces cell death in some,
but not all, cell lines sensitive to miR-26a. Although the
mechanistic details of its function in melanoma require more
study, SODD is a potential target for melanoma therapy. In
addition, our data imply that miR-26a must act on additional
targets, and that miR-26a replacement therapy is a promising
strategy for treating melanoma.
MATERIALS AND METHODS
miRNA microarrays
MicroRNAs from melanoma cell lines SK-MEL-28 and HT-144 were
compared with those from two normal melanocyte cultures. Each
sample was run in triplicate for the experiment. Total RNAs were
extracted using an miRNeasy kit (Qiagen, Valencia, CA), and then
enriched for small RNAs using an RNeasy MinElute kit (Qiagen)
SN Reuland et al.
miR-26a Is Low in Melanoma and Targets SODD
www.jidonline.org 1291
before being sent to the University of Colorado Cancer Center
Microarray Core for miRNA microarray analysis. RNA samples were
analyzed on a Bioanalyzer Small RNA chip for quality control, then
labeled and run on CombiMatrix human miRNA arrays (CombiMatrix
Diagnostics, Irvine, CA) by the Core, as directed by the manufacturer.
For data normalization, the CombiMatrix recommended method was
used: in brief, background signaling was estimated as the lowest 5%
of all signaling, including perfect matches and the mismatch controls,
and data were then normalized from the arrays using global scale
factors to bring all backgrounds to the same value. For filtering, we
removed any miRNA with no normalized signals 4200, or miRNAs
with an intensity o1,000 in all samples, and only kept miRNAs with
signaling on perfect matches that exceeded background by at least
2 , and perfect match values that exceeded 1.2 (the intensity of
the double mismatch control). We then used Rank Product statistical
analysis as reported by Breitling et al. (2004) to identify up- or down-
regulated miRNAs in melanoma compared with normal melanocytes.
The Rank Product analysis is a simple nonparametric statistical
method based on ranks of fold changes to detect differentially
expressed genes in replicated array experiments (Breitling et al.,
2004). The rank products were calculated using the same method and
procedure with Excel as described by Breitling et al. (2004).
Plasmid constructs, transfections, and luciferase reporter assays
TargetScan (http://www.targetscan.org/) was used to identify potential
miR-26a binding sites in the SODD 30UTR (called BAG4 in
TargetScan). Total RNA from melanoma cell line WM852c was used
to generate complementary DNAs and to clone the 30UTR of SODD
(NM_001204878). The SODD 30UTR is predicted to be a 568-bp
fragment (see http://www.origene.com/MicroRNA/3-UTR-Clone/
SC207066.aspx) or a B2.8-kb fragment (in TargetScan). We
attempted to amplify both the 568 bp and B2.8 kb 30UTR from
complementary DNAs of multiple melanoma cells; however, we
could only amplify the 568-bp 30UTR. It is possible that melanoma
cells mainly have the SODD transcript with the 568-bp 30UTR. Thus,
we cloned 479 bp of this 568-bp 30UTR into a pSiCheck2 reporter
plasmid at Xho1/Not1 sites for luciferase activity assays, using the
following PCR primers: 50- ACTGCTCTGCTCGAGAGCCTGTTACT
AACTTGAC-30 and 50AATTAGCGGCCGCCTGCAAATAACAAAA
CAAAACAGAAGTCC-30. The constructed psiCHECK2 plasmids were
verified by DNA sequencing (Colorado Cancer Center DNA Sequen-
cing Core). This cloned SODD 30UTR, from complementary DNAs of
melanoma cells, contains one predicted binding site for miR-26a.
HEK293 cells were cotransfected with luciferase reporter plasmids
(psiCHECK2 vector with or without indicated SODD 30UTR, 0.25mg)
and mimics of miR-26a or Allstars Negative Control siRNA (25 nM) in
24-well plates using the Lipofectamine 2000 reagent as directed by
the supplier (Invitrogen, Carlsbad, CA). After 48 hours, the cells were
lysed and assayed for luciferase activity using the Dual Luciferase
Reporter Assay kit (Promega, Madison, WI) according to the manu-
facturer’s protocol on a microplate reader (BioTek, Winooski, VT).
The psiCHECK2 reporter construct contains both firefly and Renilla
luciferase genes under the control of constitutive promoters, and
firefly luciferase activity was used as an internal control. The relative
Renilla luciferase activity was calculated as the ratio of Renilla to
firefly luciferase activity for each sample, and the relative Renilla
luciferase activities were normalized to 1.0 for negative control
cotransfected cells.
Statistics
All comparisons were evaluated by two-tailed unpaired t-tests using
the program GraphPad Prism (GraphPad Software, La Jolla, CA), with
P-values of o0.05 considered significant.
Other methods
Further information about other materials and methods used in this
work are provided in the Supplementary Material online.
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